Citadel Advisors’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Citadel Advisors’s Portfolio ASLN Stock Details ASLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-63	Closed	-$308	–	15739
2024 Q1	$308	Buy	+63	New	+$316	﹤0.01%	14364
2023 Q4	–	Sell	-200	Closed	-$2.96K	–	15506
2023 Q3	$2.96K	Buy	200 +187	+1,438%	+$3.43K	﹤0.01%	13651
2023 Q2	$365	Buy	+13	New	+$402	﹤0.01%	14141
2022 Q2	–	Sell	-300	Closed	-$11K	–	14418
2022 Q1	$11K	Buy	300 +10	+3%	+$372	﹤0.01%	13372
2021 Q4	$13K	Sell	290 -1,560	-84%	-$93.5K	﹤0.01%	13649
2021 Q3	$132K	Buy	+1,850	New	+$210K	﹤0.01%	12532

Other funds holding ASLN

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citadel Advisors's ASLN Position: Q3 2024 in Review

Citadel Advisors sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q3 2024, closing a stake of 14,709 shares — an estimated $35.3K sold.

Citadel Advisors first reported a position in ASLN in Q4 2020 and held it in 15 quarters. The position peaked at $9.56M in Q2 2021. 1 fund tracked by Wall St. Rank holds ASLN as of Q3 2024.

Citadel Advisors reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q3 2024 after selling out during the quarter.
Citadel Advisors sold 14,709 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q3 2024, an estimated $35.3K.
Citadel Advisors first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2020 and held it in 15 quarters.
Citadel Advisors's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $9.56M in Q2 2021.
1 fund tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.